Compare HRL & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRL | AXSM |
|---|---|---|
| Founded | 1891 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Meat/Poultry/Fish | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 12.0B |
| IPO Year | 1994 | 2015 |
| Metric | HRL | AXSM |
|---|---|---|
| Price | $24.75 | $255.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 17 |
| Target Price | $26.50 | ★ $211.12 |
| AVG Volume (30 Days) | ★ 4.9M | 583.5K |
| Earning Date | 05-28-2026 | 05-04-2026 |
| Dividend Yield | ★ 5.61% | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $12,106,160,000.00 | N/A |
| Revenue This Year | $2.66 | $57.24 |
| Revenue Next Year | $1.62 | $55.88 |
| P/E Ratio | $39.44 | ★ N/A |
| Revenue Growth | ★ 1.55 | N/A |
| 52 Week Low | $19.72 | $96.09 |
| 52 Week High | $31.11 | $257.44 |
| Indicator | HRL | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 76.51 | 76.03 |
| Support Level | $24.15 | $148.87 |
| Resistance Level | $24.92 | N/A |
| Average True Range (ATR) | 0.58 | 8.40 |
| MACD | 0.23 | 1.04 |
| Stochastic Oscillator | 97.88 | 98.89 |
Historically meat-focused, Hormel Foods broadened its lineup to include other protein offerings and became a branded food company. The firm sells its wares through multiple channels, including US retail (61.6% of fiscal 2025 sales), US foodservice (32.6%), and international (5.9%). By product, 73% of fiscal 2025 sales were from perishable food and 27% from shelf-stable. Major brands include Hormel, Spam, Jennie-O, Columbus, Applegate, Planters, and Skippy. Many of these hold the number one or two market share in their respective categories.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.